Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
Cristina CarterKatherine V HouserGalina V YamshchikovAbbie R BellamyJeanine MayMary E EnamaUzma SarwarBrenda LarkinRobert T BailerRichard KoupGrace L ChenShital M PatelPatricia WinokurRobert BelsheCornelia L DekkerBarney S GrahamJulie E Ledgerwoodnull nullPublished in: PloS one (2019)
All vaccination regimens were found to be safe and tolerable. While there were no overall differences between regimens, the DNA-IIV3 group by ID route, and the IIV3-IIV3 group by IM route, showed higher responses compared to the other same-route regimens.